Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials

Pulmonary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2014, Pages 241-249

  Zheng, Ya Guo ^a   Ma, Hong ^a   Hu, En Ci ^a   Liu, Gang ^a   Chen, Guo ^a   Xiong, Chang Ming ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Endothelin receptor antagonists; Meta analysis; Phosphodiesterase 5 inhibitors; Prostanoids; Pulmonary arterial hypertension; Randomized controlled trials

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE ACTIVATOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR AGONIST; PROSTANOID; RIOCIGUAT; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

ADVERSE DRUG REACTION; ARTICLE; BIBLIOGRAPHIC DATABASE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; HYPERTENSION, PULMONARY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; TREATMENT OUTCOME;

EID: 84922531779     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.08.005     Document Type: Article

References (38)

1. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30:2493-2537.
2. Benza R.L., Miller D.P., Barst R.J., Badesch D.B., Frost A.E., McGoon M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest 2012, 142:448-456.
3. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
4. Montani D., Chaumais M.C., Guignabert C., Gunther S., Girerd B., Jais X., et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014, 141:172-191.
5. Safdar Z. Targeted oral therapies in the treatment of pulmonary arterial hypertension. Clin Drug Investig 2010, 30:811-826.
6. O'Callaghan D.S., Savale L., Montani D., Jais X., Sitbon O., Simonneau G., et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011, 8:526-538.
7. Galie N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. Ameta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403.
8. He B., Zhang F., Li X., Tang C., Lin G., Du J., et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circulation J 2010, 74:1458-1464.
9. Zheng Y., Yang T., Chen G., Hu E., Gu Q., Xiong C. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol 2014, 70:13-21.
10. Simonneau G., Torbicki A., Hoeper M.M., Delcroix M., Karlocai K., Galie N., et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40:874-880.
11. Ghofrani H.A., Galiè N., Grimminger F., Grünig E., Humbert M., Jing Z.C., et al. Riociguat for the treatment of pulmonary arterial hypertension. N.Engl J Med 2013, 369:330-340.
12. Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galie N., Ghofrani H.A., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N.Engl J Med 2013, 369:809-818.
13. Tapson V.F., Jing Z.C., Xu K.F., Pan L., Feldman J., Kiely D.G., et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): a randomized controlled trial. Chest 2013, 144:952-958.
14. Jing Z.C., Parikh K., Pulido T., Jerjes-Sanchez C., White R.J., Allen R., et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013, 127:624-633.
15. Tapson V.F., Torres F., Kermeen F., Keogh A.M., Allen R.P., Frantz R.P., et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142:1383-1390.
16. Jing Z.C., Yu Z.X., Shen J.Y., Wu B.X., Xu K.F., Zhu X.Y., et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir critical care Med 2011, 183:1723-1729.
17. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
18. Simonneau G., Rubin L.J., Galie N., Barst R.J., Fleming T.R., Frost A.E., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
19. Galie N., Rubin L., Hoeper M., Jansa P., Al-Hiti H., Meyer G., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
20. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
21. Galie N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M., Lauer A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114:48-54.
22. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N.Engl J Med 2005, 353:2148-2157.
23. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galiè N., Boonstra A., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
24. Barst R.J., McGoon M., McLaughlin V., Tapson V., Oudiz R., Shapiro S., et al. Beraprost therapy for pulmonary arterial hypertension. JAm Coll Cardiol 2003, 41:2119-2125.
25. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N.Engl J Med 2002, 346:896-903.
26. Galie N., Humbert M., Vachiery J.L., Vizza C., Kneussl M., Manes A., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. JAm Coll Cardiol 2002, 39:1496-1502.
27. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
28. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin trials 1996, 17:1-12.
29. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315:629-634.
30. Barst R.J., Mubarak K.K., Machado R.F., Ataga K.I., Benza R.L., Castro O., et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010, 149:426-435.
31. Iversen K., Jensen A.S., Jensen T.V., Vejlstrup N.G., Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010, 31:1124-1131.
32. Ryerson C.J., Nayar S., Swiston J.R., Sin D.D. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 2010, 11:12.
33. Coeytaux R.R., Schmit K.M., Kraft B., Kosinski A.S., Mingo A.M., Vann L.M., et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 2014, 145:1055-1063.
34. Shi Z.L., Peng H., Hu X.W., Hu J.G. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm Pharmacol Ther 2013, 28:171-178.
35. Han B., Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet 2011, 88:586-598.
36. Liu C., Chen J., Gao Y., Deng B., Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2013, 2:CD004434.
37. Mazzanti G., Palazzini M., Dardi F., Terzi F., D'Adamo A., Rinaldi A., et al. Arandomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension. Eur Heart J 2012, 33:419.
38. Pulido T., Rubin L.J., Simonneau G. Macitentan and pulmonary arterial hypertension. N.Engl J Med 2014, 370:82-83.